Acadia Pharma (ACAD) Misses Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $26.41 --0%
EPS Growth %: -52.4%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
NEOV, MANU, CTAS, More
EPS Growth %: -52.4%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
NEOV, MANU, CTAS, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.45), $0.07 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $17 thousand versus the consensus estimate of $60 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- Increasing unusual option volume: UTHR ABUS OPRA GFL ACAD
- Union Pacific (UNP) Reiterated at Market Outperform by Citizens - Most Attractive in Rail Group
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
